title: Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Tamura
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ono
authors.forename: Motoaki
authors.initials: M
authors.lastname: Sano
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fukuda
authors.forename: Masaharu
authors.initials: M
authors.lastname: Kataoka
authors.forename: Toru
authors.initials: T
authors.lastname: Satoh
mesh_terms: D000328:Adult; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D005080:Exercise Test; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000188:drug therapy*; D009456:Neurofibromatosis 1 / Q000150:complications*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome; D014655:Vascular Resistance
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib